Jun 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

FDA Greenlights Merck’s KEYTRUDA® (pembrolizumab) Combined with Carboplatin and Paclitaxel for Treating Adults with Advanced or Recurrent Endometrial Cancer.

The U.S. Food and Drug Administration (FDA) approved diroximel fumarate, marketed under the brand name Vumerity, on October 29, 2019.

Marea Therapeutics, a biotechnology enterprise focused on clinical-stage developments and backed by Third Rock Ventures, is dedicated to creating innovative treatments for cardiometabolic disorders.

Trikafta, a combination of elexacaftor, ivacaftor, and tezacaftor, was approved by the U.S. Food and Drug Administration (FDA) on October 21, 2019.

Day One Enhances Pipeline with Innovative Clinical-Stage ADC Targeting PTK7 for Solid Tumors in Adults and Children.

The FDA granted approval for lasmiditan on October 11, 2019. This approval marked the introduction of lasmiditan as a novel treatment option for the acute management of migraine attacks in adults, with or without aura.

This trial assesses SCB-1019, Clover’s bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate, developed using the company’s proprietary Trimer-Tag vaccine technology platform.

The FDA approved Beovu on October 7, 2019, for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Spyre Therapeutics Begins Phase 1 Trial with Initial Doses of SPY001, a New Long-acting anti-α4β7 Antibody, for Inflammatory Bowel Disease Treatment.

The FDA approved trifarotene on October 4, 2019, for the treatment of acne vulgaris. It is marketed under the brand name Aklief.

FDA has approved SKYRIZI® (risankizumab-rzaa) for treating ulcerative colitis, broadening AbbVie’s inflammatory bowel disease treatment options.